Showing 1581-1590 of 2042 results for "".
- Aviceda Therapeutics Announces Formation of European Clinical Advisory Boardhttps://modernod.com/news/aviceda-therapeutics-announces-formation-of-european-clinical-advisory-board/2482218/Aviceda Therapeutics announced the formation of its European Clinical Advisory Board (CAB) made up of internationally recognized thought leaders in retina. The CAB will provide strategic consultation on the company’s clinical development of its lead asset, AVD-104, for the treatment of geog
- Cliara Awarded US Patent for Contact Lens Force Measurement Devicehttps://modernod.com/news/cliara-awarded-us-patent-for-contact-lens-force-measurement-device/2482179/Cliara has been granted a United States patent for a device designed to accurately measure the force required to remove gas-permeable contact lenses from the eye, according to a company news release. Cliara LLC is collaborating with BostonSight and LV Prasad Eye Institute
- Formosa Receives FDA Approval for Clobetasol Formulation for Treatment of Postoperative Inflammation and Painhttps://modernod.com/news/formosa-pharmaceuticals-receives-fda-approval-for-clobetasol-formulation-for-treatment-of-postoperative-inflammation-and-pain/2482142/Formosa Pharmaceuticals and AimMax Therapeutics announced that the FDA has approved clobetasol propionate ophthalmic suspension 0.05% (APP13007), for the treatment of postoperative inflammation and pain following ocular surgery. Clobetasol propionate ophthalmic suspensi
- Ascendis Pharma Forms New Ophthalmology Company Eyconishttps://modernod.com/news/ascendis-pharma-forms-new-ophthalmology-company-eyconis/2482086/Ascendis Pharma A/S announced the formation and launch of Eyconis, a company created to develop, manufacture, and commercialize TransCon ophthalmology assets globally. The new company was developed with Frazier Life Sciences, as well as an investor syndicate that includes RA Capital Man
- Bausch + Lomb Launches PreserVision AREDS 2 Formula Soft Gels Plus CoQ10 in the United Stateshttps://modernod.com/news/bausch-lomb-launches-preservision-areds-2-formula-soft-gels-plus-coq10-in-the-united-states/2481667/Bausch + Lomb announced the US launch of PreserVision AREDS 2 Formula soft gels plus coenzyme Q10 (CoQ10). Developed as a two-in-one option, Bausch + Lomb says PreserVision AREDS 2 Formula eye vitamins plus CoQ10 is the only eye vitamin that combines the exact nutrient formula
- Euclid and Visionary Optics Announce Interactive Specialty Lens Forums in Cities Across the UShttps://modernod.com/news/euclid-and-visionary-optics-announce-interactive-specialty-lens-forums-in-cities-across-the-us/2481620/Euclid Vision is joining forces with Visionary Optics to host multiple specialty contact lens dinner discussions in cities around the US. The program,
- Formosa and AimMax Submit NDA to the FDA for APP13007 for Postoperative Inflammation and Pain After Ocular Surgeryhttps://modernod.com/news/formosa-and-aimmax-announce-the-nda-submission-to-the-fda-for-app13007-for-postoperative-inflammation-and-pain-following-ocular-surgery/2481602/Formosa Pharmaceuticals and AimMax Therapeutics announced the submission of a new drug application to the FDA for APP13007, a novel aqueous nanosuspension formulation of the corticosteroid, clobetasol propionate (0.05%), for the treatment of inflammation and pain following ocular surger
- New Analysis of MRI Findings Show Uplizna Reduced the Formation of Asymptomatic Optic Nerve Lesions in People with NMOSDhttps://modernod.com/news/new-analysis-of-mri-findings-show-uplizna-reduced-the-formation-of-asymptomatic-optic-nerve-lesions-in-people-with-nmosd/2481467/Horizon Therapeutics announced the presentation of new MRI imaging data from the phase 3 clinical trial showing Uplizna (inebilizumab-cdon) reduced the formation of subclinical (asymptomatic) optic nerve lesions in people with Neuromyelitis Optica Spectrum Disorder (NMOSD). These findin
- Eyenovia Announces Development Collaboration with Formosa Pharmaceuticalshttps://modernod.com/news/eyenovia-announces-development-collaboration-with-formosa-pharmaceuticals/2481412/Eyenovia announced that the company has entered into a development collaboration agreement with Taiwan-based Formosa Pharmaceuticals that seeks to combine Eyenovia’s Optejet dispensing technology with Formosa’s APNT nanoparticle formulation platform for the potential develop
- Harrow Launches Next-Generation Compounded Atropine Formulationshttps://modernod.com/news/harrow-launches-next-generation-compounded-atropine-formulations/2481410/Harrow announced the launch of its patent-pending, next-generation compounded atropine formulations. The formulations are now available through Harrow’s wholly owned compounding and mail order pharmacy subsidiary, ImprimisRx. According to Harrow, the ImprimisRx